Access the full text.
Sign up today, get DeepDyve free for 14 days.
J. Koo, W. Jung, Joon Jeong (2010)
Metastatic Breast Cancer Shows Different Immunohistochemical Phenotype According to Metastatic SiteTumori Journal, 96
Jieqiong Liu, H. Deng, W. Jia, Yunjie Zeng, N. Rao, Shunrong Li, L. Jin, Jiannan Wu, E. Song, F. Su (2012)
Comparison of ER/PR and HER2 statuses in primary and paired liver metastatic sites of breast carcinoma in patients with or without treatmentJournal of Cancer Research and Clinical Oncology, 138
C. Simmons, N. Miller, W. Geddie, D. Gianfelice, M. Oldfield, G. Dranitsaris, M. Clemons (2009)
Does confirmatory tumor biopsy alter the management of breast cancer patients with distant metastases?Annals of Oncology, 20
A. Giuliano, D. Hawes, K. Ballman, Pat Whitworth, P. Blumencranz, D. Reintgen, M. Morrow, A. Leitch, K. Hunt, L. Mccall, A. Abati, R. Cote (2011)
Association of occult metastases in sentinel lymph nodes and bone marrow with survival among women with early-stage invasive breast cancer.JAMA, 306 4
M. Dowsett, T. Nielsen, R. A’Hern, J. Bartlett, R. Coombes, J. Cuzick, M. Ellis, N. Henry, J. Hugh, T. Lively, L. McShane, S. Paik, F. Penault-Llorca, Ljudmila Prudkin, M. Regan, J. Salter, C. Sotiriou, I. Smith, G. Viale, J. Zujewski, D. Hayes (2011)
Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.Journal of the National Cancer Institute, 103 22
T. Sørlie, C. Perou, R. Tibshirani, T. Aas, S. Geisler, H. Johnsen, T. Hastie, M. Eisen, M. Rijn, S. Jeffrey, T. Thorsen, H. Quist, J. Matese, P. Brown, D. Botstein, P. Lønning, A. Børresen-Dale (2001)
Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 98
C. Denkert, J. Blohmer, B. Müller, H. Eidtmann, W. Eiermann, B. Gerber, H. Tesch, J. Hilfrich, J. Huober, T. Fehm, J. Barinoff, C. Jackisch, J. Prinzler, T. Rüdiger, J. Budczies, E. Erbstoesser, S. Loibl, G. Minckwitz (2012)
Abstract S4-5: Ki67 levels in pretherapeutic core biopsies as predictive and prognostic parameters in the neoadjuvant GeparTrio trialCancer Research, 72
T. Kuukasjärvi, J. Kononen, H. Helin, K. Holli, J. Isola (1996)
Loss of estrogen receptor in recurrent breast cancer is associated with poor response to endocrine therapy.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 14 9
P. Dubsky, M. Filipits, R. Jakesz, M. Rudas, C. Singer, R. Greil, O. Dietze, I. Luisser, E. Klug, R. Sedivy, M. Bachner, D. Mayr, M. Schmidt, M. Gehrmann, C. Petry, K. Weber, R. Kronenwett, J. Brase, M. Gnant (2012)
EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancerAnnals of Oncology, 24
J. Mansi, H. Gogas, A.J. Biss, J. Gazet, U. Berger, R. Coombes (1999)
Outcome of primary-breast-cancer patients with micrometastases: a long-term follow-up studyThe Lancet, 354
E. Amir, N. Miller, W. Geddie, O. Freedman, F. Kassam, C. Simmons, M. Oldfield, G. Dranitsaris, G. Tomlinson, A. Laupacis, I. Tannock, M. Clemons (2012)
Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 6
E. Azambuja, F. Cardoso, G. Castro, M. Colozza, M. Mano, V. Durbecq, C. Sotiriou, D. Larsimont, M. Piccart-Gebhart, M. Paesmans (2007)
Ki-67 as prognostic marker in early breast cancer: a meta-analysis of published studies involving 12 155 patientsBritish Journal of Cancer, 96
J. Zidan, I. Dashkovsky, C. Stayerman, W. Basher, C. Cozacov, A. Hadary (2005)
Comparison of HER-2 overexpression in primary breast cancer and metastatic sites and its effect on biological targeting therapy of metastatic diseaseBritish Journal of Cancer, 93
Y. Gong, D. Booser, N. Sneige (2005)
Comparison of HER‐2 status determined by fluorescence in situ hybridization in primary and metastatic breast carcinomaCancer, 103
R. Elledge, W. McGuire (1992)
Prognostic factors and therapeutic decisions in axillary node-negative breast cancer.Annual review of medicine, 44
N. Niikura, Jun Liu, N. Hayashi, E. Mittendorf, Y. Gong, S. Palla, Y. Tokuda, A. González-Angulo, G. Hortobagyi, N. Ueno (2012)
Loss of human epidermal growth factor receptor 2 (HER2) expression in metastatic sites of HER2-overexpressing primary breast tumors.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 6
C. Xiao, C. Xiao, Yun Gong, Eric Han, A. González-Angulo, N. Sneige (2011)
Stability of HER2-positive status in breast carcinoma: a comparison between primary and paired metastatic tumors with regard to the possible impact of intervening trastuzumab treatment.Annals of oncology : official journal of the European Society for Medical Oncology, 22 7
H. Chang, Sae-Won Han, D. Oh, S. Im, Y. Jeon, I. Park, W. Han, D. Noh, Y. Bang, Tae-You Kim (2011)
Discordant human epidermal growth factor receptor 2 and hormone receptor status in primary and metastatic breast cancer and response to trastuzumab.Japanese journal of clinical oncology, 41 5
C. Tapia, S. Savic, U. Wagner, R. Schönegg, H. Novotny, B. Grilli, M. Herzog, A. Barascud, I. Zlobec, G. Cathomas, L. Terracciano, G. Feichter, L. Bubendorf (2007)
HER2 gene status in primary breast cancers and matched distant metastasesBreast Cancer Research, 9
Kelly Lear-Kaul, Hye-Ryoung Yoon, B. Kleinschmidt-DeMasters, L. Mcgavran, Meenakshi Singh (2009)
Her-2/neu status in breast cancer metastases to the central nervous system.Archives of pathology & laboratory medicine, 127 11
M. Filipits, M. Rudas, R. Jakesz, P. Dubsky, F. Fitzal, C. Singer, O. Dietze, R. Greil, Andrea Jelen, P. Sevelda, C. Freibauer, V. Müller, F. Jänicke, Marcus Schmidt, H. Kölbl, A. Rody, M. Kaufmann, W. Schroth, H. Brauch, M. Schwab, P. Fritz, K. Weber, I. Feder, G. Hennig, R. Kronenwett, M. Gehrmann, M. Gnant (2011)
A New Molecular Predictor of Distant Recurrence in ER-Positive, HER2-Negative Breast Cancer Adds Independent Information to Conventional Clinical Risk FactorsClinical Cancer Research, 17
A. Fabi, A. Benedetto, G. Metro, L. Perracchio, C. Nisticó, F. Filippo, Cristiana Ercolani, G. Ferretti, E. Melucci, S. Buglioni, I. Sperduti, P. Papaldo, F. Cognetti, M. Mottolese (2011)
HER2 Protein and Gene Variation between Primary and Metastatic Breast Cancer: Significance and Impact on Patient CareClinical Cancer Research, 17
H. Lacroix, Iglehart Jd, Skinner Ma, Kraus Mh (1989)
Overexpression of erbB-2 or EGF receptor proteins present in early stage mammary carcinoma is detected simultaneously in matched primary tumors and regional metastases.Oncogene, 4 2
L. Harris, H. Fritsche, R. Mennel, L. Norton, P. Ravdin, S. Taube, M. Somerfield, D. Hayes, R. Bast (2007)
American Society of Clinical Oncology 2007 Update of Recommendations for the Use of Tumor Markers in Breast Cancer.Journal of oncology practice, 3 6
(2010)
Tamoxifen citrate , letrozole , anastrozole , or exemestane with or without chemotherapy in treating patients with invasive RxPONDER breast cancer
S. Taucher, M. Rudas, R. Mader, M. Gnant, P. Dubsky, T. Bachleitner, S. Roka, F. Fitzal, D. Kandioler, E. Sporn, J. Friedl, M. Mittlböck, R. Jakesz (2003)
Do we need HER‐2/neu testing for all patients with primary breast carcinoma?Cancer, 98
L Harris, H Fritsche, R Mennel, L Norton, P Ravdin, S Taube (2007)
American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancerJ Clin Oncol, 25
Liling Zhang, S. Riethdorf, Gang Wu, Tao Wang, Kunyu Yang, G. Peng, Junli Liu, K. Pantel (2012)
Meta-Analysis of the Prognostic Value of Circulating Tumor Cells in Breast CancerClinical Cancer Research, 18
E. Sarı, G. Guler, M. Hayran, I. Gullu, K. Altundağ, Y. Ozişik (2011)
Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancerMedical Oncology, 28
M. Look, W. Putten, M. Duffy, N. Harbeck, I. Christensen, C. Thomssen, R. Kates, F. Spyratos, M. Fernö, S. Eppenberger-Castori, C. Sweep, K. Ulm, J. Peyrat, P. Martin, H. Magdelenat, N. Brünner, C. Duggan, B. Lisboa, P. Bendahl, V. Quillien, A. Daver, G. Ricolleau, M. Gelder, P. Manders, W. Fiets, M. Blankenstein, P. Broët, S. Romain, G. Daxenbichler, G. Windbichler, T. Čufer, S. Borstnar, W. Kueng, L. Beex, J. Klijn, N. O’higgins, U. Eppenberger, F. Jänicke, M. Schmitt, J. Foekens (2002)
Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.Journal of the National Cancer Institute, 94 2
S. Paik, S. Shak, G. Tang, Chungyeul Kim, J. Baker, M. Cronin, F. Baehner, M. Walker, D. Watson, T. Park, W. Hiller, E. Fisher, D. Wickerham, J. Bryant, N. Wolmark, Genomic Health, Redwood City, S. Francisco (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer.The New England journal of medicine, 351 27
R. Broom, P. Tang, C. Simmons, L. Bordeleau, A. Mulligan, F. O'Malley, N. Miller, I. Andrulis, D. Brenner, M. Clemons (2009)
Changes in estrogen receptor, progesterone receptor and Her-2/neu status with time: discordance rates between primary and metastatic breast cancer.Anticancer research, 29 5
E. Rakha (2013)
Pitfalls in outcome prediction of breast cancerJournal of Clinical Pathology, 66
R. Duchnowska, R. Dziadziuszko, T. Trojanowski, T. Mandat, W. Och, B. Czartoryska-Arłukowicz, B. Radecka, W. Olszewski, F. Szubstarski, W. Kozlowski, B. Jarosz, W. Rogowski, A. Kowalczyk, J. Limon, W. Biernat, J. Jassem (2012)
Conversion of epidermal growth factor receptor 2 and hormone receptor expression in breast cancer metastases to the brainBreast Cancer Research : BCR, 14
Argha Nandy, S. Gangopadhyay, A. Mukhopadhyay (2014)
Individualizing breast cancer treatment-The dawn of personalized medicine.Experimental cell research, 320 1
L. Hoefnagel, M. Vijver, H. Slooten, P. Wesseling, J. Wesseling, P. Westenend, J. Bart, C. Seldenrijk, I. Nagtegaal, J. Oudejans, P. Valk, P. Groep, E. Vries, E. Wall, P. Diest (2010)
Receptor conversion in distant breast cancer metastasesBreast Cancer Research : BCR, 12
Ann Knoop, S. Bentzen, M. Nielsen, B. Rasmussen, C. Rose (2001)
Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 19 14
S. Chia, B. Norris, C. Speers, Maggie Cheang, B. Gilks, A. Gown, D. Huntsman, I. Olivotto, T. Nielsen, K. Gelmon (2008)
Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 35
D. Gancberg, A. Leo, F. Cardoso, G. Rouas, M. Pedrocchi, M. Paesmans, A. Verhest, C. Bernard‐Marty, M. Piccart, D. Larsimont (2002)
Comparison of HER-2 status between primary breast cancer and corresponding distant metastatic sites.Annals of oncology : official journal of the European Society for Medical Oncology, 13 7
M. Cristofanilli, G. Budd, M. Ellis, A. Stopeck, J. Matera, M. Miller, J. Reuben, G. Doyle, W. Allard, L. Terstappen, D. Hayes (2004)
Circulating tumor cells, disease progression, and survival in metastatic breast cancer.The New England journal of medicine, 351 8
M. Pestrin, S. Bessi, F. Puglisi, A. Minisini, G. Masci, N. Battelli, A. Ravaioli, L. Gianni, R. Marsico, C. Tondini, S. Gori, C. Coombes, J. Stebbing, L. Biganzoli, M. Buyse, A. Leo (2012)
Final results of a multicenter phase II clinical trial evaluating the activity of single-agent lapatinib in patients with HER2-negative metastatic breast cancer and HER2-positive circulating tumor cells. A proof-of-concept studyBreast Cancer Research and Treatment, 134
S. Johnston, G. Saccani‐Jotti, I. Smith, J. Salter, J. Newby, M. Coppen, S. Ebbs, M. Dowsett (1995)
Changes in estrogen receptor, progesterone receptor, and pS2 expression in tamoxifen-resistant human breast cancer.Cancer research, 55 15
A. González-Angulo, J. Ferrer-Lozano, K. Stemke‐Hale, A. Sahin, Shuying Liu, J. Barrera, O. Burgués, A. Lluch, Huiqin Chen, G. Hortobagyi, G. Mills, F. Meric-Bernstam (2011)
PI3K Pathway Mutations and PTEN Levels in Primary and Metastatic Breast CancerMolecular Cancer Therapeutics, 10
R. Arisio, A. Sapino, P. Cassoni, G. Accinelli, M. Cuccorese, M. Mano, G. Bussolati (2000)
What modifies the relation between tumour size and lymph node metastases in T1 breast carcinomas?Journal of Clinical Pathology, 53
A. Prat, J. Parker, O. Karginova, C. Fan, C. Livasy, Jason Herschkowitz, Xiaping He, C. Perou (2010)
Phenotypic and molecular characterization of the claudin-low intrinsic subtype of breast cancerBreast Cancer Research : BCR, 12
A. Vincent-Salomon, M. Jouve, P. Génin, P. Fréneaux, B. Sigal‐Zafrani, M. Caly, P. Beuzeboc, P. Pouillart, X. Sastre-Garau (2002)
HER2 status in patients with breast carcinoma is not modified selectively by preoperative chemotherapy and is stable during the metastatic processCancer, 94
E. Lower, E. Glass, D. Bradley, R. Blau, S. Heffelfinger (2005)
Impact of metastatic estrogen receptor and progesterone receptor status on survivalBreast Cancer Research and Treatment, 90
L. Lindström, E. Karlsson, U. Wilking, U. Johansson, J. Hartman, E. Lidbrink, T. Hatschek, L. Skoog, J. Bergh (2012)
Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 30 21
S. Dawood, A. González-Angulo (2012)
To biopsy or not to biopsy: is that the only question?The oncologist, 17 2
G. Curigliano, V. Bagnardi, G. Viale, L. Fumagalli, N. Rotmensz, G. Aurilio, M. Locatelli, G. Pruneri, S. Giudici, M. Bellomi, P. Vigna, L. Monfardini, F. Orsi, F. Nolè, E. Munzone, A. Goldhirsch (2011)
Should liver metastases of breast cancer be biopsied to improve treatment choice?Annals of oncology : official journal of the European Society for Medical Oncology, 22 10
B. Müller, E. Keil, A. Lehmann, K. Winzer, C. Richter-Ehrenstein, J. Prinzler, N. Bangemann, A. Reles, S. Stadie, W. Schoenegg, J. Eucker, Marcus Schmidt, F. Lippek, K. Jöhrens, S. Pahl, B. Sinn, J. Budczies, M. Dietel, C. Denkert (2013)
The EndoPredict Gene-Expression Assay in Clinical Practice - Performance and Impact on Clinical DecisionsPLoS ONE, 8
W. Janni, F. Vogl, G. Wiedswang, Marit Synnestvedt, T. Fehm, J. Jückstock, E. Borgen, B. Rack, S. Braun, H. Sommer, E. Solomayer, K. Pantel, J. Nesland, K. Friese, B. Naume (2011)
Persistence of Disseminated Tumor Cells in the Bone Marrow of Breast Cancer Patients Predicts Increased Risk for Relapse—A European Pooled AnalysisClinical Cancer Research, 17
A. Thompson, L. Jordan, P. Quinlan, E. Anderson, A. Skene, J. Dewar, C. Purdie (2010)
Prospective comparison of switches in biomarker status between primary and recurrent breast cancer: the Breast Recurrence In Tissues Study (BRITS)Breast Cancer Research : BCR, 12
E. Perez, V. Suman, N. Davidson, S. Martino, P. Kaufman, W. Lingle, P. Flynn, J. Ingle, D. Visscher, R. Jenkins (2006)
HER2 testing by local, central, and reference laboratories in specimens from the North Central Cancer Treatment Group N9831 intergroup adjuvant trial.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 19
E. Lower, E. Glass, R. Blau, S. Harman (2008)
HER-2/neu expression in primary and metastatic breast cancerBreast Cancer Research and Treatment, 113
S. Ven, V. Smit, T. Dekker, J. Nortier, J. Kroep (2010)
Discordances in ER, PR and HER2 receptors after neoadjuvant chemotherapy in breast cancer.Cancer treatment reviews, 37 6
B. Leyland-Jones, B. Smith (2011)
Serum HER2 testing in patients with HER2-positive breast cancer: the death knell tolls.The Lancet. Oncology, 12 3
Yixin Wang, J. Klijn, Yi Zhang, A. Sieuwerts, M. Look, Fei Yang, D. Talantov, M. Timmermans, M. Gelder, Jack Yu, T. Jatkoe, E. Berns, D. Atkins, J. Foekens (2005)
Gene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancerThe Lancet, 365
NCT 00382018 . S 0500 Treatment decision making based on blood levels of tumor cells in women with metastatic breast cancer receiving chemotherapy
E. Botteri, D. Disalvatore, G. Curigliano, J. Brollo, V. Bagnardi, G. Viale, F. Orsi, A. Goldhirsch, N. Rotmensz (2012)
Biopsy of liver metastasis for women with breast cancer: impact on survival.Breast, 21 3
D. Berry, C. Cirrincione, I. Henderson, M. Citron, D. Budman, L. Goldstein, S. Martino, E. Perez, H. Muss, L. Norton, C. Hudis, E. Winer (2006)
Estrogen-receptor status and outcomes of modern chemotherapy for patients with node-positive breast cancer.JAMA, 295 14
S. Paik, G. Tang, S. Shak, Chungyeul Kim, J. Baker, W. Kim, M. Cronin, F. Baehner, D. Watson, J. Bryant, J. Costantino, C. Geyer, D. Wickerham, N. Wolmark (2006)
Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptor-positive breast cancer.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 24 23
N. Turner, A. Leo (2013)
HER2 discordance between primary and metastatic breast cancer: assessing the clinical impact.Cancer treatment reviews, 39 8
E. Mamounas, G. Tang, B. Fisher, S. Paik, S. Shak, J. Costantino, D. Watson, C. Geyer, D. Wickerham, N. Wolmark (2010)
Association between the 21-gene recurrence score assay and risk of locoregional recurrence in node-negative, estrogen receptor-positive breast cancer: results from NSABP B-14 and NSABP B-20.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 10
S. Meng, D. Tripathy, S. Shete, R. Ashfaq, B. Haley, S. Perkins, P. Beitsch, Amanullah Khan, D. Euhus, C. Osborne, E. Frenkel, S. Hoover, M. Leitch, E. Clifford, E. Vitetta, L. Morrison, D. Herlyn, L. Terstappen, T. Fleming, T. Fehm, T. Tucker, N. Lane, Jianqiang Wang, J. Uhr (2004)
HER-2 gene amplification can be acquired as breast cancer progresses.Proceedings of the National Academy of Sciences of the United States of America, 101 25
Jang-Fang Kuo, Wea‐Long Lin, Chih‐Ping Han (2011)
Detection of minimal residual disease in blood and bone marrow in early stage breast cancerCancer, 117
E. Rakha, D. El-Rehim, C. Paish, A. Green, Andrew Lee, J. Robertson, R. Blamey, D. Macmillan, I. Ellis (2006)
Basal phenotype identifies a poor prognostic subgroup of breast cancer of clinical importance.European journal of cancer, 42 18
S. Dawood, R. Hu, Michelle Homes, L. Collins, S. Schnitt, J. Connolly, G. Colditz, R. Tamimi (2011)
Defining breast cancer prognosis based on molecular phenotypes: results from a large cohort studyBreast Cancer Research and Treatment, 126
L. Veer, H. Dai, M. Vijver, Yudong He, A. Hart, M. Mao, H. Peterse, K. Kooy, M. Marton, A. Witteveen, G. Schreiber, R. Kerkhoven, C. Roberts, P. Linsley, R. Bernards, S. Friend (2002)
Gene expression profiling predicts clinical outcome of breast cancerNature, 415
K. Albain, W. Barlow, S. Shak, G. Hortobagyi, R. Livingston, I. Yeh, P. Ravdin, R. Bugarini, F. Baehner, N. Davidson, G. Sledge, E. Winer, C. Hudis, J. Ingle, E. Perez, K. Pritchard, L. Shepherd, J. Gralow, C. Yoshizawa, D. Allred, C. Osborne, D. Hayes (2010)
Prognostic and predictive value of the 21-gene recurrence score assay in postmenopausal women with node-positive, oestrogen-receptor-positive breast cancer on chemotherapy: a retrospective analysis of a randomised trial.The Lancet. Oncology, 11 1
V. Grann, A. Troxel, N. Zojwalla, J. Jacobson, D. Hershman, A. Neugut (2005)
Hormone receptor status and survival in a population‐based cohort of patients with breast carcinomaCancer, 103
M. Dowsett, J. Cuzick, C. Wale, J. Forbes, E. Mallon, J. Salter, E. Quinn, A. Dunbier, M. Baum, A. Buzdar, A. Howell, R. Bugarini, F. Baehner, S. Shak (2010)
Prediction of risk of distant recurrence using the 21-gene recurrence score in node-negative and node-positive postmenopausal patients with breast cancer treated with anastrozole or tamoxifen: a TransATAC study.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 28 11
R. Rouzier, C. Perou, W. Symmans, N. Ibrahim, M. Cristofanilli, K. Anderson, K. Hess, J. Stec, J. Stec, M. Ayers, P. Wagner, P. Morandi, Chang Fan, Islam Rabiul, J. Ross, G. Hortobagyi, L. Pusztai (2005)
Breast Cancer Molecular Subtypes Respond Differently to Preoperative ChemotherapyClinical Cancer Research, 11
N. Harbeck, M. Schmitt, C. Meisner, C. Friedel, M. Untch, M. Schmidt, C. Sweep, B. Lisboa, M. Lux, T. Beck, S. Hasmüller, M. Kiechle, F. Jänicke, C. Thomssen (2013)
Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.European journal of cancer, 49 8
A. Insa, A. Lluch, F. Prósper, I. Marugán, A. Martínez-agulló, J. Garcia-conde (1999)
Prognostic factors predicting survival from first recurrence in patients with metastatic breast cancer: analysis of 439 patientsBreast Cancer Research and Treatment, 56
W. McGuire, G. Clark (1992)
Prognostic factors and treatment decisions in axillary-node-negative breast cancer.The New England journal of medicine, 326 26
E. Mittendorf, Yun Wu, M. Scaltriti, F. Meric-Bernstam, K. Hunt, S. Dawood, F. Esteva, A. Buzdar, Huiqin Chen, Sameena Eksambi, G. Hortobagyi, J. Baselga, A. González-Angulo (2009)
Loss of HER2 Amplification Following Trastuzumab-Based Neoadjuvant Systemic Therapy and Survival OutcomesClinical Cancer Research, 15
Paul Romain, R. Madan, O. Tawfik, I. Damjanov, Fang Fan (2012)
Organotropism and prognostic marker discordance in distant metastases of breast carcinoma: fact or fiction? A clinicopathologic analysis.Human pathology, 43 3
The analysis of biomarkers in breast cancer has made a large impact in treatment decisions and determining prognosis. Information gained from the phenotypic and molecular profile helps both in prognostic stratification as well as treatment selection. With the advent of newer more efficacious chemotherapeutic and biological agents in the management of metastatic breast cancer, most women with this disease are exposed to multiple lines of therapy. Discordance in the receptor status between the primary and metastatic sites is frequently encountered and may play an important role in deciding subsequent therapy. In this review, we look at the role of current biomarkers in the management of breast cancer, which are promising and the therapeutic and prognostic implications of their discordance during the natural course of disease progression.
Current Breast Cancer Reports – Springer Journals
Published: Oct 19, 2013
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.